logo
ProjectPending

BioVac - Kili

Pending · South Africa

Source: International Finance Corporation (IFC)

In 2023 IFC invested in Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd (“Biovac” or “the company”) to support it to expand its suite of products to reduce Africa’s dependence on imported vaccines. This included partnering with Pfizer-BioNTech through a tech transfer agreement for fill and finish of vaccines. IFC is now considering another investment in the company to support furth

Status
Prospective
Sector
Hydrogen, Biomass, Manufacturing (Industrial), Commercial, Waste Processing and Treatment, Hospital, Government
Location
South Africa
Updated
19 Nov 2026
Source
International Finance Corporation (IFC)

ConstructChat

Ask ConstructChat about BioVac - Kili

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “BioVac - Kili” is an infrastructure initiative in the Hydrogen sector, located in South Africa. Taiyo aggregates data on it from International Finance Corporation (IFC).

Participants

Sponsoring Agency

Status

Original status

pending

Taiyo status

Prospective

Taiyo last update

2026-11-19

Contact

Not available for this record.

Description

Description

In 2023 IFC invested in Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd (“Biovac” or “the company”) to support it to expand its suite of products to reduce Africa’s dependence on imported vaccines. This included partnering with Pfizer-BioNTech through a tech transfer agreement for fill and finish of vaccines. IFC is now considering another investment in the company to support further expansion into sub-Saharan African markets, with the objective of supplying vaccines under Global Alliance for Vaccines and Immunization program. Biovac’s existing facility is located in an industrial area in Cape Town, South Africa, where it manufacturers vaccines and has its offices. These vaccines are provided to the South African Department of Health, accounting for approximately 60% of the national vaccine supply.IFC’s new investment will assist the company with the development of a new vaccine manufacturing facility on vacant land adjacent to the existing operations (the “new facility” or the “project”). Biovac is in the process of acquiring the site for the project from the City of Cape Town. The facility will include a glass vial fill-and-finish suite, a drug substance suite and a blow-fill-seal plastic line. The product portfolio will consist of multiple new vaccines targeting key diseases prevalent in Africa including Pneumococcal Conjugate Vaccine (PCV), Meningococcal Vaccine (Mening-X), Inactivated Polio Vaccine (IPV), Oral Cholera Vaccine (OCV), and Rotavirus Vaccine. Construction is scheduled to commence in 2026, with commercial manufacturing operations starting in 2029.The project cost is to be financed through a combination of debt, equity, and grant funding from various funders. IFC’s component of the financing will consist of a US$20 million IFC A Loan and a US$90 million in Parallel Loans.

Original sector

G-FA - Pharmaceuticals and Medicine Manufacturing

Location

Country

South Africa

Source

Source

International Finance Corporation (IFC)

URL

More Details

Record type

Project

Sector

Hydrogen, Biomass, Manufacturing (Industrial), Commercial, Waste Processing and Treatment, Hospital, Government

Article published date

2025-12-10

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project